CDK4/6 Inhibition With Lerociclib is a Potential Therapeutic Strategy for the Treatment of Pediatric Sarcomas
Author / Expert
Janet R. Julson, Sara C. Horton, Colin H. Quinn, Andee M. Beierle, Laura V. Bownes, Jerry E. Stewart, Jamie Aye, Karina J. Yoon, Elizabeth A. Beierle
Topic overview
Sarcomas are a heterogenous collection of bone and soft tissue tumors. The heterogeneity of these tumors makes it difficult to standardize treatment. CDK 4/6 inhibitors are a family of targeted agents which limit cell cycle progression and have been shown to be upregulated in sarcomas. In the current preclinical study, we evaluated the effects of lerociclib, a CDK4/6 inhibitor, on pediatric sarcomas in vitro and in 3D bioprinted tumors.
Comments